Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity

Immune checkpoint inhibitors (ICIs) have become an essential part of treatment for many cancer types. These monoclonal antibodies remove a critical negative regulatory signal that allows the immune system to recognize and destroy malignant cells that were previously undetectable. Unfortunately, thei...

Descripción completa

Detalles Bibliográficos
Autores principales: Bylsma, Sophia, Yun, Karen, Patel, Sandip, Dennis, Michael J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Lung Cancer (TA Leal and N Sethakorn, Section Editors)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402751/
https://www.ncbi.nlm.nih.gov/pubmed/35876957
http://dx.doi.org/10.1007/s11864-022-00995-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402751/
https://www.ncbi.nlm.nih.gov/pubmed/35876957
http://dx.doi.org/10.1007/s11864-022-00995-9

Ejemplares similares